Literature DB >> 24589272

Modulators of erythropoiesis: emerging therapies for hemoglobinopathies and disorders of red cell production.

Laura Breda1, Stefano Rivella2.   

Abstract

Use of new compound such as inhibitors of JAK2 or transforming growth factor β-like molecules might soon revolutionize the treatment of β-thalassemia and related disorders. However, this situation requires careful optimization, noting the potential for off-target immune suppression for JAK2 inhibitors and the lack of mechanistic insights for the use of the ligand trap soluble molecules that sequester ligands of activin receptor IIA and B.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ACE-011; ACE-536; Hemoglobinopathies; JAK2; LY-2157299; Steady state; Stress and ineffective erythropoiesis; Transforming growth factor β

Mesh：

Substances：

Year:  2014        PMID： 24589272      PMCID： PMC3970239          DOI： 10.1016/j.hoc.2013.12.001

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN： 0889-8588            Impact factor:   3.722


  77 in total

Review 1.  β-thalassemia: a model for elucidating the dynamic regulation of ineffective erythropoiesis and iron metabolism.

Authors:  Yelena Ginzburg; Stefano Rivella
Journal:  Blood       Date:  2011-07-18       Impact factor: 22.113

2.  Smad6 inhibits signalling by the TGF-beta superfamily.

Authors:  T Imamura; M Takase; A Nishihara; E Oeda; J Hanai; M Kawabata; K Miyazono
Journal:  Nature       Date:  1997-10-09       Impact factor: 49.962

3.  Stromal cell-mediated inhibition of erythropoiesis can be attenuated by Sotatercept (ACE-011), an activin receptor type II ligand trap.

Authors:  Camelia Iancu-Rubin; Goar Mosoyan; Jiapeng Wang; Thomas Kraus; Victoria Sung; Ronald Hoffman
Journal:  Exp Hematol       Date:  2012-12-20       Impact factor: 3.084

4.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

Authors:  Ross L Levine; Martha Wadleigh; Jan Cools; Benjamin L Ebert; Gerlinde Wernig; Brian J P Huntly; Titus J Boggon; Iwona Wlodarska; Jennifer J Clark; Sandra Moore; Jennifer Adelsperger; Sumin Koo; Jeffrey C Lee; Stacey Gabriel; Thomas Mercher; Alan D'Andrea; Stefan Fröhling; Konstanze Döhner; Peter Marynen; Peter Vandenberghe; Ruben A Mesa; Ayalew Tefferi; James D Griffin; Michael J Eck; William R Sellers; Matthew Meyerson; Todd R Golub; Stephanie J Lee; D Gary Gilliland
Journal:  Cancer Cell       Date:  2005-04       Impact factor: 31.743

Review 5.  Follistatin as a potent regulator of bone metabolism.

Authors:  A Gajos-Michniewicz; A W Piastowska; J A Russell; T Ochedalski
Journal:  Biomarkers       Date:  2010-06-22       Impact factor: 2.658

6.  Expression cloning of the murine erythropoietin receptor.

Authors:  A D D'Andrea; H F Lodish; G G Wong
Journal:  Cell       Date:  1989-04-21       Impact factor: 41.582

7.  The importance of erythroid expansion in determining the extent of apoptosis in erythroid precursors in patients with beta-thalassemia major.

Authors:  F Centis; L Tabellini; G Lucarelli; O Buffi; P Tonucci; B Persini; M Annibali; R Emiliani; A Iliescu; S Rapa; R Rossi; L Ma; E Angelucci; S L Schrier
Journal:  Blood       Date:  2000-11-15       Impact factor: 22.113

8.  Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease.

Authors:  Sonia Vallet; Siddhartha Mukherjee; Nileshwari Vaghela; Teru Hideshima; Mariateresa Fulciniti; Samantha Pozzi; Loredana Santo; Diana Cirstea; Kishan Patel; Aliyah R Sohani; Alex Guimaraes; Wanling Xie; Dharminder Chauhan; Jesse A Schoonmaker; Eyal Attar; Michael Churchill; Edie Weller; Nikhil Munshi; Jasbir S Seehra; Ralph Weissleder; Kenneth C Anderson; David T Scadden; Noopur Raje
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-01       Impact factor: 11.205

Review 9.  Targeting the TGFβ signalling pathway in disease.

Authors:  Rosemary J Akhurst; Akiko Hata
Journal:  Nat Rev Drug Discov       Date:  2012-09-24       Impact factor: 84.694

10.  JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin.

Authors:  B A Witthuhn; F W Quelle; O Silvennoinen; T Yi; B Tang; O Miura; J N Ihle
Journal:  Cell       Date:  1993-07-30       Impact factor: 41.582
View more
  11 in total

Review 1.  β-thalassemias: paradigmatic diseases for scientific discoveries and development of innovative therapies.

Authors:  Stefano Rivella
Journal:  Haematologica       Date:  2015-04       Impact factor: 9.941

Review 2.  Anemia: progress in molecular mechanisms and therapies.

Authors:  Vijay G Sankaran; Mitchell J Weiss
Journal:  Nat Med       Date:  2015-03       Impact factor: 53.440

Review 3.  Hepcidin agonists as therapeutic tools.

Authors:  Carla Casu; Elizabeta Nemeth; Stefano Rivella
Journal:  Blood       Date:  2018-03-09       Impact factor: 22.113

Review 4.  How we manage iron overload in sickle cell patients.

Authors:  Thomas D Coates; John C Wood
Journal:  Br J Haematol       Date:  2017-03-14       Impact factor: 6.998

Review 5.  Iron age: novel targets for iron overload.

Authors:  Carla Casu; Stefano Rivella
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2014-11-18

6.  Heterogeneity of the bone marrow niche in patients with myeloproliferative neoplasms: ActivinA secretion by mesenchymal stromal cells correlates with the degree of marrow fibrosis.

Authors:  Benedetta Rambaldi; Elisa Diral; Samantha Donsante; Noemi Di Marzo; Federica Mottadelli; Lucia Cardinale; Erica Dander; Giuseppe Isimbaldi; Pietro Pioltelli; Andrea Biondi; Mara Riminucci; Giovanna D'Amico; Elena Maria Elli; Alice Pievani; Marta Serafini
Journal:  Ann Hematol       Date:  2020-10-21       Impact factor: 3.673

Review 7.  What can we learn from ineffective erythropoiesis in thalassemia?

Authors:  Paraskevi Rea Oikonomidou; Stefano Rivella
Journal:  Blood Rev       Date:  2017-10-03       Impact factor: 8.250

8.  The European Hematology Association Roadmap for European Hematology Research: a consensus document.

Authors:  Andreas Engert; Carlo Balduini; Anneke Brand; Bertrand Coiffier; Catherine Cordonnier; Hartmut Döhner; Thom Duyvené de Wit; Sabine Eichinger; Willem Fibbe; Tony Green; Fleur de Haas; Achille Iolascon; Thierry Jaffredo; Francesco Rodeghiero; Gilles Salles; Jan Jacob Schuringa
Journal:  Haematologica       Date:  2016-01-27       Impact factor: 9.941

Review 9.  β-Thalassemia.

Authors:  Raffaella Origa
Journal:  Genet Med       Date:  2016-11-03       Impact factor: 8.822

10.  The Red Blood Cells on the Move!

Authors:  Anna Bogdanova; Lars Kaestner
Journal:  Front Physiol       Date:  2018-05-01       Impact factor: 4.566
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.